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Hemostatic Function and Progressing Ischemic Stroke
D-dimer Predicts Early Clinical Progression
Mark Barber, MRCP; Peter Langhorne, PhD, FRCP; Ann Rumley, PhD;
Gordon D.O. Lowe, MD, FRCP; David J. Stott, MD, FRCP
Background and Purpose—Early clinical progression of ischemic stroke is common and is associated with increased risk
of death and dependency. We hypothesized that activation of the coagulation system is an important contributor in some
cases of deterioration. We aimed to characterize alterations in circulating hemostatic markers in patients with
progressing stroke.
Methods—Consecutive acute ischemic stroke admissions were recruited. Progressing stroke was defined by deterioration
in components of the Scandinavian Stroke Scale. Hemostatic markers (coagulation factors VIIc, VIIIc, and IXc,
prothrombin fragments 12 [F12], thrombin–antithrombin complexes [TAT], D-dimer, fibrinogen, von Willebrand
factor [vWF] and tissue plasminogen activator) were measured within 24 hours of symptom recognition.
Results—Fifty-four (25%) of the 219 patients met criteria for progressing stroke. F12 (median 1.28 versus 1.06 nmol/L,
P0.01), TAT (5.28 versus 4.07 g/L, P0.01), D-dimer (443 versus 194 ng/mL, P0.001) and vWF (216 versus 198
IU/dL, P0.05) levels were higher in these patients than in stable/improving patients. In logistic regression analysis,
with all important clinical and laboratory variables included, only natural log D-dimer (odds ratio [OR]: 1.87; 95%
confidence interval [CI]: 1.38 to 2.54; P0.0001) and mean arterial blood pressure (OR: 1.26 per 10 mm Hg change;
95% CI: 1.05 to 1.51; P0.01) remained independent predictors of progressing stroke.
Conclusions—There is evidence of excess thrombin generation and fibrin turnover in patients with progressing ischemic
stroke. Measurement of D-dimer levels can identify patients at high risk for stroke progression. Further research is
required to determine whether such patients benefit from acute interventions aimed at modifying hemostatic function.
(Stroke. 2004;35:1421-1425.)
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Early clinical progression of ischemic stroke is commonand is associated with poor prognosis.1–3 Hemostatic
activation may be an important cause, or contributor, to
progressing ischemic stroke. There is evidence of increased
thrombin generation and fibrin turnover, altered fibrinolytic
activity, and disturbed endothelial function in acute stroke.4–8
There is little evidence to date regarding alterations in
hemostatic measures and stroke progression. A small Japa-
nese study found elevated thrombin–antithrombin complex
(TAT) and fibrin D-dimer levels in patients with progressing
stroke when samples were withdrawn within 7 days of
symptom onset.9 As part of a heparin intervention study, de
Boer et al found a trend toward elevated admission serum
fragment E levels in patients who later had motor progres-
sion.10 Analysis of baseline variables in the National Institute
of Neurological Disorders and Stroke (NINDS) rt-PA Stroke
Trial demonstrated that fibrin degradation product levels
were independently associated with late, but not early, clin-
ical deterioration.11
Trials of interventions (such as heparin) that potentially alter
hemostatic function in ischemic stroke have so far proved
negative in terms of preventing neurological deterioration in the
first days after stroke;12,13 perhaps partly because reduced
thrombus formation is balanced by an increased risk of intracra-
nial and extracranial hemorrhage. These studies, however, did
not target patients likely to be at a high risk for progressing
stroke. We hypothesized that circulating hemostatic markers
would predict progressing ischemic stroke. This study aimed to
characterize alterations in these markers in ischemic stroke
patients with progressing neurological signs, compared with
patients without such progression. If measuring blood markers
of hemostatic function could identify patients at high risk for
progressing ischemic stroke, this might allow more effective
targeting of early antithrombotic therapy to prevent progressing
stroke and improve clinical outcome.
Subjects and Methods
Patients were recruited from consecutive ischemic stroke admissions
to a large urban teaching hospital between April 2002 and October
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2003. Patients were excluded if any of the following criteria were
met: a delay of 24 hours from symptom recognition to admission,
age younger than 18 years, coma (only responding to pain on
admission),14 or epileptic seizure activity. Patients who were antico-
agulated before admission were also excluded. No recruited patients
were prescribed thrombolysis or heparin in the first 72 hours after
stroke onset. All patients were treated on a standardized protocol for
the management of dehydration (2.5 L of 0.9% sodium chloride
solution intravenously, over the first 24 hours, unless contraindi-
cated), hyperglycemia, hypoxia, and pyrexia.
A single experienced examiner saw all patients. Assessment
included clinical classification (Oxfordshire Community Stroke
Project [OCSP] classification15) and measurement of stroke severity
using the Scandinavian Stroke Scale (SSS).16 Blood pressure was
measured noninvasively using the Passport II multiparameter mon-
itoring system (Datascope Corporation). Follow-up was at 30 days
using the Rankin scale and Barthel Index.17,18
Progressing stroke was defined using a modification of the
European Progressing Stroke Study (EPSS) criteria.14 The EPSS
definition of progressing stroke requires a reduction of 2 SSS
points in conscious level or eye movements or leg or arm motor
power between baseline and day 3, a reduction of 3 SSS points in
speech score, or both. Progression cannot be said to have occurred if
the conscious level improves significantly between the 2 assess-
ments, even if there has been a worsening of other domains. For the
purpose of this analysis, eye movement changes were excluded,
because there is concern about reliability of this domain of the
SSS.19,20 Removing the gaze palsy component of the EPSS definition
does little to change its validity.14
Blood samples were separated and plasma aliquots stored at
80°C before analysis. Plasma viscosity was measured at 37°C
using a semiautomated capillary viscometer (Coulter Electronics).
Fibrinogen was measured by the Clauss method using a MDA180
coagulometer (Biomerieux) with reagents from the manufacturer.
The calibrant used was the 8th British Standard (NIBSC). Plasma
levels of fibrin D-dimer and tissue plasminogen activator (t-PA)
antigen were measured with commercially available enzyme-linked
immunosorbent assays from Biopool AB. Plasma von Willebrand
factor (vWF) antigen levels were measured using an enzyme-linked
immunosorbent assays using rabbit antihuman polyclonal antibodies
obtained from DAKO (High Wycombe). Highly sensitive C-reactive
protein (CRP) was measured immunologically using the BN ProSpec
nephelometer (Dade Behring) using calibrants and reagents provided
by the manufacturer. Prothrombin fragment 12 (F12) and TAT
were measured using commercially available enzyme-linked immu-
nosorbent assays from Dade Behring (Milton Keynes). Activated
partial thromboplastin time and coagulation factors VIIc, VIIIc, and
IXc were measured by standard clotting assays on an automated
coagulometer (MDA 180; Biomerieux) using calibrants and reagents
provided by the manufacturer. Activated protein C ratio was mea-
sured on the MDA 180 using the Chromogenix Coatest kit from
Quadratec. The local research ethics committee approved this study.
Statistical Analysis
Power calculations were based on the findings of Uchiyama et al9
and assumed a 25% rate of progressing stroke. For 90% power
(P0.05), to determine similar abnormalities in TAT and D-dimer
TABLE 1. Demographic and Clinical Differences Between Patients With Progressing Stroke
and Those With Stable or Improving Stroke
Variable
Progressing Stroke
n54
No Progression
n165 P
Age (y) 74 (65–83) 71 (62–78) 0.02
Female 36 (67%) 84 (51%) 0.04
Prestroke Rankin 3–5 11 (20%) 28 (17%) 0.57
Previous hypertension 31 (57%) 80 (48%) 0.26
Known diabetes 9 (17%) 24 (15%) 0.70
Previous stroke 9 (17%) 39 (24%) 0.28
Antiplatelet therapy 26 (48%) 76 (46%) 0.69
Current smoker 22 (41%) 56 (34%) 0.41
Clinical Differences
Admission delay (h) 5 (2–13) 6 (2–12) 0.76
Left hemisphere lesion 29 (54%) 89 (54%) 0.98
OCSP classification
TACI 25 (46%) 39 (24%) 0.01
PACI 22 (41%) 71 (43%)
LACI 5 (9%) 42 (25%)
POCI 2 (4%) 13 (8%)
Admission SSS score (minus gait) (points) 30.5 (20–40) 39 (26–42) 0.01
Admission MABP (mm Hg) 111 (20) 106 (20) 0.10
Atrial fibrillation on ECG 12 (22%) 17 (10%) 0.03
Pyrexia 37.5°C in first 72 h 24 (44%) 46 (28%) 0.02
Aspirin prescribed between admission and
venipuncture
0 (0%) 2 (1%) 1.00
For continuous variables, results are expressed as median (interquartile range) except for blood pressure, for which
results are expressed as mean (standard deviation).
OCSP indicates Oxfordshire Community Stroke Project; TACI, total anterior circulation infarct; PACI, partial anterior
circulation infarct; LACI, lacunar infarct; POCI, posterior circulation infarct; SSS, Scandinavian Stroke Scale; MABP,
mean arterial blood pressure.
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levels, it was estimated that a total group size of 189 patients would
be required.
Results are expressed as medians throughout the text unless
otherwise stated. For univariate comparison of categorical variables,
the Pearson 2 was used. For nonnormally distributed hemostatic
variables, transformations to normality were made where possible.
Univariate analysis of normally distributed and transformed vari-
ables was by the unpaired t test. For other nonnormally distributed
continuous variables, the Mann–Whitney U test was used. Multivar-
iate analysis was by step-wise binary logistic regression. Variables
were included in this analysis when significance levels in univariate
analysis fell below P0.10. OCSP classification was included in the
model as a categorical variable. All analyses were performed using
SPSS for Windows version 9.0.
Results
Of 474 admissions assessed, 280 patients were initially
considered as potentially suitable for recruitment to the study.
Sixty-one of these were subsequently excluded, because they
did not meet our inclusion criteria (these exclusions were
made blind to results of the blood analyses). This left a
database of 219 patients for further analysis, of whom 54
(25%) met the criteria for progressing stroke.
Important demographic differences between the progress-
ing stroke patients and the stable/ improving patients are
shown in Table 1. Significant differences included older age
(74 versus 71 years, P0.02) and a higher prevalence of
female gender (67% versus 51%, P0.04) in the progressing
group. Clinical differences between the progressing stroke
patients and the stable/improving patients are also illustrated
in Table 1. Admission neurological deficit, as measured by
the SSS, was more severe (30.5 versus 39 points, P0.01)
and there was a higher prevalence of OCSP classification
total anterior circulation infarctions in the progressing group
(46% versus 24%, P0.01). There was a trend toward higher
mean arterial blood pressure (mean 111 versus 106 mm Hg,
P0.099), and there was a higher prevalence of atrial
fibrillation on admission electrocardiogram (22% verus 10%,
P0.03) in the progressing stroke group.
Patients with progressing stroke had significantly elevated
levels of prothrombin fragments 12 (1.28 versus 1.06
nmol/L, P0.01), TAT complexes (5.28 versus 4.07 g/L,
P0.009), fibrin D-dimer (443 versus 194 ng/mL, P0.001)
and vWF (216 versus 198 IU/dL, P0.05) compared with
patients with no progression (see Table 2). These patients also
had higher leukocyte counts (10.25 versus 9.30109/L,
P0.02) and CRP levels (8.66 versus 5.26 mg/L, P0.05) on
univariate analysis. The results of a logistic regression model
of predictors of progressing stroke are shown in Table 3. Of
all demographic, clinical, and hemostatic variables, only
mean arterial blood pressure (odds ratio: 1.26 for each
10 mm Hg increase) and D-dimer (odds ratio: 1.87 for each
natural log unit increase) were independently associated with
progressing stroke. The area under the receiver-operating
characteristic curve for D-dimer as a predictor of progressing
stroke was 0.678 (95% confidence interval: 0.600 to 0.756).
Outcome was poorer in the progressing stroke group.
Death was more common at 30 days (33% versus 5%,
P0.001) and there were also important differences with
respect to outcomes in survivors as measured using the
Rankin scale and Barthel Index (results not presented).
TABLE 2. Circulating Hemostatic and Hemorheological Variables in Patients With Progressing
Stroke and Those With Stable or Improving Stroke
Variable
Progressing Stroke
n54
No Progression
n165 P
Time from admission to venipuncture (h) 11 (4–15) 8 (3–16) 0.541
Factor VIIc (IU/dL) 139 (111–171) 148 (127–165) 0.126
Factor VIIIc (IU/dL) 204 (166–240) 195 (162–235) 0.150
Factor IXc (IU/dL) 170 (148–188) 157 (142–184) 0.085
Prothrombin F12 (nmol/L) 1.28 (0.92–1.74) 1.06 (0.76–1.48) 0.011
Thrombin-antithrombin complexes (g/L) 5.28 (3.90–8.46) 4.07 (3.28–6.25) 0.009
Fibrin D-dimer (ng/mL) 443 (164–1091) 194 (92–481) 0.001
APC ratio (n164) 2.73 (2.44–3.07) 2.81 (2.53–3.12) 0.430
Tissue plasminogen activator antigen (ng/mL) 12.7 (8.9–18.0) 11.0 (8.2–15.2) 0.102
von Willebrand Factor antigen (IU/dL) 216 (178–273) 198 (157–244) 0.045
Plasma viscosity (mPa.s) 1.32 (1.21–1.38) 1.26 (1.20–1.34) 0.066
Hematocrit 0.40 (0.37–0.43) 0.40 (0.36–0.43) 0.467
Fibrinogen (g/L) 3.97 (3.50–5.02) 3.90 (3.16–4.54) 0.079
C-reactive protein (mg/L) 8.66 (3.69–30.45) 5.26 (1.64–18.4) 0.049
Leukocyte count (109/L) 10.25 (8.05–12.78) 9.30 (7.4–11.5) 0.017
Results are expressed as median (interquartile range).
APC indicates activated protein C.
TABLE 3. Step-Wise Logistic Regression Model of Predictors
of Progressing Ischemic Stroke
B (SE) R Odds Ratio P
Constant 7.297 (1.531)
MABP (per 10 mm Hg) 0.233 (0.093) 0.140 1.26 0.01
Natural log D-dimer 0.628 (0.156) 0.254 1.87 0.0001
All variables with P0.10 in univariate analysis were included in this model.
MABP indicates mean arterial blood pressure.
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Hospital stay was significantly longer in surviving patients
with progressing stroke (67 versus 13 days, P0.001).
Discussion
We have confirmed that progressing ischemic stroke is a
common problem that is associated with high morbidity and
mortality. Our important new findings, in this large prospec-
tive study, are that a number of hemostatic variables are
higher in those patients admitted with ischemic stroke who
later deteriorate. In particular, once other potentially impor-
tant factors are taken into consideration, fibrin D-dimer levels
independently predict progressing stroke.
F12 and TAT are markers of thrombin generation,
whereas D-dimer (a fibrin degradation product) is a marker
not only of thrombin generation but also of cross-linked fibrin
turnover. D-dimer is the most stable of these 3 measures.21
Previous studies demonstrated evidence of early activation of
the coagulation system in patients with acute stroke, when
compared with nonstroke controls. Measured markers in-
cluded raised F12, TAT, and D-dimer levels.4–8 Admission
D-dimer may also play a role in differentiating between
stroke subtypes.4 In our study, these 3 markers of coagulation
activation were each significantly raised in patients with
progressing stroke. Only D-dimer levels, however, remained
statistically significant after multivariate analysis.
There are plausible mechanisms through which D-dimer
levels could be closely related to progressing stroke. In-
creased D-dimer levels may reflect ongoing thrombus forma-
tion within cerebral vessels or may be a marker of systemic
hypercoagulability. A small study of selected stroke patients
suggested that duration of arterial occlusion, as demonstrated
on serial transcranial Doppler, was significantly associated
with neurological progression.22 Transcranial Doppler evi-
dence of middle cerebral artery asymmetry or “no-flow”
within 6 hours of stroke has predictive value for stroke
progression/improvement.23
Some markers of hemostatic function are acute-phase
reactants; D-dimer is one of these. Hence, it is possible that
elevated D-dimer levels in patients with progressing stroke
are simply a marker of a more severe stroke (there was an
excess of total anterior circulation infarctions in this group),
as part of a reactant inflammatory process. Bacterial infection
(mainly chest and urinary tract) and venous thrombosis are
other possible contributors, although these usually occur after
the first week.24 We have minimized these possibilities by
withdrawing samples soon after admission. We have also
included other recognized acute-phase reactants (CRP, fi-
brinogen, and leukocyte count), together with recorded epi-
sodes of pyrexia in the first 72 hours, in our analysis.
Adjustment of the association of D-dimer with progressing
stroke for these inflammatory indices did not account for the
association. There is, in fact, some evidence that fibrin
degradation products, including D-dimer, may act to stimu-
late the inflammatory process,25–28 and this might provide a
further pathological mechanism through which D-dimer is
linked to progressing stroke.29,30
The finding that admission mean arterial blood pressure
independently predicts progressing stroke is interesting. This
mirrors findings of our previous retrospective case control
study3 and those of other groups.22,23,31 An exception to these
findings was the study of Jørgensen et al, which showed an
inverse relationship between systolic blood pressure and the
incidence of deterioration.32 The relevance of these findings
is uncertain, because there is not enough evidence to support
interventions for deliberately altering blood pressure in acute
stroke.33
This study has a number of strengths. Patients were
recruited from consecutive admissions to a general hospital,
few exclusion criteria were used, and a single observer made
all assessments. Samples were obtained relatively early after
admission and a validated definition of progressing stroke
was used.14 Our study also has potential weaknesses. Blood
samples were not taken at the time of admission but instead
were withdrawn as soon as was practical (and always within
24 hours of symptom recognition). A number of different
commercial D-dimer assays are available, and so our results
may not necessarily be generalized to all assays.
Our analysis cannot exclude the possibility that elevated
coagulation markers predated the acute event. These patients
may have had widespread vascular disease before stroke
onset and are, therefore, likely to have increased pre-event
levels when compared with population controls. The mea-
sured levels in the present study, however, far exceed those
recorded even in a population of patients with clinical
atherosclerosis who later have stroke.34 Acute and convales-
cent samples suggest that D-dimer levels may decrease over
the months after acute stroke.35 The difference in levels
between those patients with progressing stroke and stable
patients also suggest that D-dimer elevations are connected,
in some way, to an acute process rather than to chronic
inflammation and atherosclerosis.
We cannot be certain of all the mechanisms responsible for
the excessive elevation of D-dimer in the acute phase of
progressing stroke. The extent of local arterial thrombosis and
tissue death is likely to be important (as reflected by the
excess of total anterior circulation infarctions in the progress-
ing stroke group), although other systemic factors may be
important in some patients. We have, however, shown in our
analysis that measurement of D-dimer, a cheap and widely
available assay, independently predicts progressing stroke.
This provides useful prognostic information, but may also be
helpful in selecting patients who could benefit from interven-
tions aimed at preventing early neurological deterioration
after ischemic stroke; in particular, those specifically targeted
at manipulating the coagulation system.
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